The association between breast cancer and glioblastoma multiforme has not been amply analyzed in the literature. We describe 11 female patients with a diagnosis of glioblastoma multiforme who were treated when younger for breast cancer. We believe that this association is not due to chance but rather to genetic changes in hormone status and in particular to sex hormones. Another important point of view is represented by the chemotherapy treatment of breast cancer, which could have a carcinogenic effect and explain the growth of glioblastoma. This consideration, in our opinion, is important, because more effort should be made to understand the pathogenesis of glioblastoma multiforme and to improve the therapeutic approaches.
CapocacciaR., VerdecchiaA., MicheliA.: Breast cancer incidence and prevalence estimated from survival and mortality. Cancer Causes Control, 1: 23–29, 1990.
2.
VerdecchiaA., De AngelisG., CapocacciaR.: Estimation and projections of cancer prevalence from cancer registry data. Stat Med, 30: 3511–3526, 2002.
3.
ParkinD.M., WhelanS.L., FerlayJ. (Eds): Cancer incidence in five continents. Vol VIIIARC Sci Publ; (143): I-XXXIV, 1–1240, 1997.
4.
VerdecchiaA., CapocacciaR., ChessaE., De AngelisG., MicheliA., ValenteF.: Incidence and prevalence of respiratory tumors in Italy. Estimation from mortality data. Ann Ist Superiore Sanità, 28: 91–105, 1992.
5.
KleihuesP., BurgerP.C., CollinsV.P., NewcombE.W., OhgakiH., CaveneeW.K.: Glioblastoma. In: Pathology and genetics of tumors of the nervous system, KleihuesP., CaveneeW.K., (Eds), pp 29–39, IARC Press, Lyon, 2000.
6.
CusterB.S., KoepsellT.D., MuellerB.A.: The association between breast carcinoma and meningioma in women. Cancer, 94: 1626–1635, 2002.
7.
RaizerJ.J., MalkinM.G., KleberM., AbreyL.E.: Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy. Neuro Oncol, 6: 247–252, 2004.
8.
KhanR.B., RaizerJ.J., MalkinM.G., BazylewiczK.A., AbreyL.E.: A phase II study of extended low-dose temozolomide in recurrent malignant gliomas. Neurol Oncol, 4: 39–43, 2002.
9.
Sanson M, Cartalat-Carel S, Taillibert S, Napolitano M, Djafari L, Cougnard J, Gervais H, Laigle F, Carpentier A, Mokhtari K, Taillandier L, Chinot O, Duffau H, Honnorat J, Hoang-Xuan K, Delattre JY, ANOCEF group:Initial chemotherapy in gliomatosis cerebri. Neurology, 63: 270–275, 2004.
10.
TuettenbergJ., GrobholzR., KornT., WenzF., ErberR., VajkoczyP.: Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme. J Cancer Res Clin Oncol, 131: 31–40, 2005.
11.
PoyhonenL., HeikkinenJ., VehkalahtiI.: Two different primary tumors of the brain in a patient with breast cancer. Eur J Nucl Med, 4: 483–484, 1979.
12.
GastautJ.L., KoeppelM.C., AlliezB., MichelB., GambarelliD., MartinP.M.: Triple tumor association: breast cancer, meningioma and glioblastoma. Rev Neurol, 143: 753–758, 1987.
13.
Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BAJ, Gayther SA, Birch JM, Lindblom A, Stoppa-Lyonnet D, Bignon Y, Borg A, Hamann U, Haites N, Scott RJ, Maugard CM, Vasen H, Seitz S, Cannon-Albright LA, Schofield A, Zelada-Hedman M and the Breast Cancer Linkage Consortium:Genetic heterogeneity and penetrance analysis of the BCRA1 and BCRA2 genes in breast cancer families. Am J Hum Genet, 62: 676–689, 1998.
14.
VarleyJ.M., EvansD.G.R., BirchJ.M.: Li-Fraumeni syndrome: a molecular and clinical review. Brit J Cancer76, 1–14, 1997.
15.
LiawD., MarchD.J., LiJ., DahiaP.L.M., WangS.I., ZhengZ., BoseS., CallK.M., TsouH.C., PeacokeM., EngC., ParsonsR.: Germline mutation of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nature (Genet), 16: 64–67, 1997.
16.
LiJ., YenC., LiawD., PodsypaninaK., BoseS., WangS.I., PucJ., MiliaresisC., RodgersL., McCombieR., BignerS.H., GiovanellaB.C., IttmannM., TyckoB., HibshooshH., WiglerM.H., ParsonsR.: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science, 275: 1943–1947, 1997.
17.
SteckP.A., PershouseM.A., JasserS.A., YungW.K., LinH., LigonA.H., LangfordL.A., BaumgardM.L., HattierT., DavisT., FryeC., HuR., SwedlundB., TengD.H., TavtigianS.V.: Identification of a candidate tumor suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nature (Genet), 15: 356–362, 1997.
18.
TranY., BenbatoulK., GorseK., RempelS., FutrealA., GreenM., NewshamI.: Novel regions of allelic deletion on chromosome 18p in tumors of the lung, brain and breast. Oncogene, 17: 3499–3505, 1998.
19.
TomsS.A., HercbergsA., LiuJ., KondoS., HaqqiT., CaseyG., IwasakiK., BarnettG.H., BarnaB.P.: Antagonist effect of insulin-like growth factor I on protein kinase inhibitor-mediated apoptosis in human glioblastoma cells in association with bcl-2 and bcl-xL. J Neurosurg, 88: 884–889, 1998.
20.
LiC.I., DalingJ.R., MaloneK.E.: Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998. J Clin Oncol, 21: 28–34, 2003.
21.
PlunkettR.J., LisA., BaroneT.A., FronckowiakM.D., GreenbergS.J.: Hormonal effects on glioblastoma multiforme in the nude rat model. J Neurosurg, 90: 1072–1077, 1999.
22.
McKinleyB.P., MichalekA.M., FenstermakerR.A., PlunkettR.J.: The impact of age and sex on the incidence of glial tumors in New York State between 1976 and 1995. J Neurosurg, 93: 932–939, 2000.
23.
InoueT., AkahiraJ., SuzukiT., DarnelA.D., KanekoC., TakahashiK., HatoriM., ShiraneR., KumabeT., KurokawaY., SatomiS., SasanoH.: Progesterone production and actions in the human central nervous system and neurogenic tumors. J Clin Endocrinol Metab, 87: 5325–5331, 2002.
24.
AssimakopoulouM., Sotiropoulou BonikouG., MaraziotisT., VarakisJ.: Does sex steroid receptor status have any prognostic or predictive significance in brain astrocytic tumors?Clin Neuropathol, 17: 27–34, 1998.
25.
ValagussaP., MoliterniA., TerenzianiM., ZambettiM., BonadonnaG.: Second malignancies following CMF-based adjuvant chemotherapy in resectable breast cancer. Ann Oncol, 5: 803–809, 1994.
26.
MalufF.C., DeAngelisL.M., RaizerJ.J., AbreyL.E.: High-grade gliomas in patients with prior systemic malignancies. Cancer, 94: 3219–3224, 2002.
